Business
Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
Durable Glycemic and C-Peptide Improvements with Icovamenib in Insulin-Deficient Type 2 DiabetesSAN CARLOS, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it presented COVALENT-111 study results at the 23rd WCIRDC which took place December 3-6, 2025 in Los Angeles, California. The data showed durable glycemic and c-peptide improvements with icovamenib,
About this update from Biomea Fusion, Inc.
[{"type":"image","alt":"Biomea Fusion, Inc.","displaySize":"","headline":null,"caption":"Biomea Fusion, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":80,"url":"https://media.zenfs.com/en/globenewswire.com/23ef33094735e204421f6d8274b615e3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gkukhuOJZCy6sOBr1Udv6Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/23ef33094735e204421f6d8274b615e3","width":300,"height":80}},"lazy":false},{"type":"text","content":"Durable Glycemic and C-Peptide Improvements with Icovamenib in Insulin-Deficient Type 2 Diabetes","length":96,"tagName":"p"},{"type":"text","content":"SAN CARLOS, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it presented COVALENT-111 study results at the 23rd WCIRDC which took place December 3-6, 2025 in Los Angeles, California. The data showed durable glycemic and c-peptide improvements with icovamenib, a menin inhibitor targeting beta-cell restoration in insulin deficient type 2 diabetes.","length":492,"tagName":"p"},{"type":"text","content":"“I am very pleased that our data was selected for an oral presentation at the WCIRDC meeting this year. Over the past 24 months, our clinical studies have shown that selective inhibition of menin can meaningfully influence the clinical response of patients with insulin deficient diabetes. The results we presented at this meeting highlight the lasting and continuous benefits observed in in our study, with durable glycemic and C-peptide improvements 9 months after the last dose,” said Mick Hitchcock, Ph.D., Interim CEO and Board Member of Biomea Fusion. “Targeting menin offers promise for people living with diabetes, with the potential to support the natural insulin producing capacity of the pancreatic beta cells. Icovamenib, as a selective menin inhibitor, represents a first in class approach in this area of research.”","length":829,"tagName":"p"},{"type":"text","content":"Key Highlights from WCIRDC showing HbA1c and C-peptide responses at week 52 – 9 months post the last dose:","length":106,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Icovamenib demonstrated durable and continuous treatment effect ...